ArticleGenome medicine2012
Serum metabolomic profile as a means to distinguish stage of colorectal cancer.
Article in Genome medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Metabolomic Pathway Activity with Genomic Single-Nucleotide Polymorphisms Associated with Colorectal Cancer Recurrence and 5-Year Overall Survival.Journal of gastrointestinal cancer · 2023Pooled it
- Early detection of treatment futility in patients with metastatic colorectal cancer.Oncotarget · 2022Trial
- A machine-learned predictor of colonic polyps based on urinary metabolomics.BioMed research international · 2013Trial
- Serum metabolomics modelling reveals stage-associated purine and endocannabinoid metabolic signatures in colorectal cancer progression.Frontiers in oncology · 2026Article
- Multi-omics in colorectal cancer liver metastasis: applications and research advances.Cancer biology & medicine · 2025Review
- Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer.Molecular oncology · 2025Article
- NMR-based metabolomics combined with metabolic pathway analysis reveals metabolic heterogeneity of colorectal cancer tissue at different anatomical locations and stages.International journal of cancer · 2025Article
- Development of a urine-based metabolomics approach for multi-cancer screening and tumor origin prediction.Frontiers in immunology · 2024Article
- Review
- Identifying metabolic features of colorectal cancer liability using Mendelian randomization.eLife · 2023Article
- Identifying metabolic features of colorectal cancer liability using Mendelian randomization.medRxiv : the preprint server for health sciences · 2023Article
- Correlations for untargeted GC × GC-HRTOF-MS metabolomics of colorectal cancer.Metabolomics : Official journal of the Metabolomic Society · 2023Article
- Gut Microbial and Associated Metabolite Markers for Colorectal Cancer Diagnosis.Microorganisms · 2023Review
- Quantitative plasma profiling byFrontiers in molecular biosciences · 2023Article
- Practical Aspects of NMR-Based Metabolomics.Handbook of experimental pharmacology · 2023Article
- Article
- Changing Metabolic Patterns along the Colorectal Adenoma-Carcinoma Sequence.Journal of clinical medicine · 2022Article
- Serum Colorectal Cancer Biomarkers Unraveled by NMR Metabolomics: Past, Present, and Future.Analytical chemistry · 2022Article
- Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection.Frontiers in oncology · 2022Article
- 1H-NMR Based Metabolomics Technology Identifies Potential Serum Biomarkers of Colorectal Cancer Lung Metastasis in a Mouse Model.Cancer management and research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPresently, colorectal cancer (CRC) is staged preoperatively by radiographic tests, and postoperatively by pathological evaluation of available surgical specimens. However, present staging methods do not accurately identify occult metastases. This has a direct effect on clinical management. Early identification of metastases isolated to the liver may enable surgical resection, whereas more disseminated disease may be best treated with palliative chemotherapy.
methodsSera from 103 patients with colorectal adenocarcinoma treated at the same tertiary cancer center were analyzed by proton nuclear magnetic resonance (1H NMR) spectroscopy and gas chromatography-mass spectroscopy (GC-MS). Metabolic profiling was done using both supervised pattern recognition and orthogonal partial least squares-discriminant analysis (O-PLS-DA) of the most significant metabolites, which enables comparison of the whole sample spectrum between groups. The metabolomic profiles generated from each platform were compared between the following groups: locoregional CRC (N = 42); liver-only metastases (N = 45); and extrahepatic metastases (N = 25).
resultsThe serum metabolomic profile associated with locoregional CRC was distinct from that associated with liver-only metastases, based on 1H NMR spectroscopy (P = 5.10 × 10-7) and GC-MS (P = 1.79 × 10-7). Similarly, the serum metabolomic profile differed significantly between patients with liver-only metastases and with extrahepatic metastases. The change in metabolomic profile was most markedly demonstrated on GC-MS (P = 4.75 × 10-5).
conclusionsIn CRC, the serum metabolomic profile changes markedly with metastasis, and site of disease also appears to affect the pattern of circulating metabolites. This novel observation may have clinical utility in enhancing staging accuracy and selecting patients for surgical or medical management. Additional studies are required to determine the sensitivity of this approach to detect subtle or occult metastatic disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.